Effective at the opening of trading on the Effective Date, the Company’s pre-consolidated common shares will be delisted from the Exchange and the post-consolidated common shares will commence trading ...

CFO Joe Vazzano disclosed that Abeona had $98.1 million in cash and equivalents as of December 31, 2024, providing financial resources to fund operations into 2026 without considering potential pz-cel ...

Ladenburg, Germany, 21 March 2025 – Heidelberg Pharma AG (FSE: HPHA) today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024) and its outlook ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma.

The Adeno Associated Virus Vector Manufacturing market, valued at USD 1,148.4 million in 2024, is expected to register robust revenue CAGR of 19.6%.Request free copy of this report:  March 14, 2025 - ...

Anthony Bergmann; Chief Financial Officer; Capricor Therapeutics Inc. Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc. Edward T ...

Commercial Metals Company today announced financial results for its fiscal second quarter ended February 28, 2025. Second quarter net earnings was $25.5 million, or $0.22 per diluted share, on net ...

Marlon Brown, a recently licensed trainer, has been elected as the new president of the United Racehorse Trainers’ ...

Tropical Battery is gearing up to launch its much-anticipated additional public offer (APO) with plans to bring it to market ...

London stocks fell in early trade on Friday as data showed that UK borrowing significantly overshot expectations in February, ...

Enrollment completed in Phase 2a CBeyond trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead ...